P81 Bedside measurement of exhaled breath condensate hydrogen peroxide differentiates lung cancer and interstitial lung disease from healthy controls

2019 ◽  
Author(s):  
DM Lodge ◽  
D Neville ◽  
T Brown ◽  
H Rupani ◽  
KS Babu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Hydrogen Peroxide ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Exhaled Breath Condensate ◽  
Exhaled Breath ◽  
Healthy Controls ◽  
Breath Condensate

scholarly journals The VICTORY (Investigation of Inflammacheck to Measure Exhaled Breath Condensate Hydrogen Peroxide in Respiratory Conditions) Study: Protocol for a Cross-sectional Observational Study

10.2196/23831 ◽  
2021 ◽  
Vol 10 (7) ◽  
pp. e23831
Author(s):  
Lauren Fox ◽  
Jessica Gates ◽  
Ruth De Vos ◽  
Laura Wiffen ◽  
Alexander Hicks ◽  
...  
Keyword(s):  
Health Care ◽  
Hydrogen Peroxide ◽  
Observational Study ◽  
Lung Disease ◽  
Exhaled Breath Condensate ◽  
Exhaled Breath ◽  
Cross Sectional ◽  
Handheld Device ◽  
Respiratory Conditions ◽  
Breath Condensate

Background More than 7% of the world’s population is living with a chronic respiratory condition. In the United Kingdom, lung disease affects approximately 1 in 5 people, resulting in over 700,000 hospital admissions each year. People with respiratory conditions have several symptoms and can require multiple health care visits and investigations before a diagnosis is made. The tests available can be difficult to perform, especially if a person is symptomatic, leading to poor quality results. A new, easy-to-perform, point-of-care test that can be performed in any health care setting and that can differentiate between various respiratory conditions would have a significant, beneficial impact on the ability to diagnose respiratory diseases. Objective The objective of this study is to use a new handheld device (Inflammacheck) in different respiratory conditions to measure the exhaled breath condensate hydrogen peroxide (EBC H2O2) and compare these results with those of healthy controls and with each other. This study also aims to determine whether the device can measure other parameters, including breath humidity, breath temperature, breath flow dynamics, and end tidal carbon dioxide. Methods We will perform a single-visit, cross-sectional observational study of EBC H2O2 levels, as measured by Inflammacheck, in people with respiratory disease and volunteers with no known lung disease. Participants with a confirmed diagnosis of asthma, chronic obstructive pulmonary disease, lung cancer, bronchiectasis, pneumonia, breathing pattern disorder, and interstitial lung disease as well as volunteers with no history of lung disease will be asked to breathe into the Inflammacheck device to record their breath sample. Results The results from this study will be available in 2022, in anticipation of COVID-19–related delays. Conclusions This study will investigate the EBC H2O2, as well as other exhaled breath parameters, for use as a future diagnostic tool.

scholarly journals The VICTORY (Investigation of Inflammacheck to Measure Exhaled Breath Condensate Hydrogen Peroxide in Respiratory Conditions) Study: Protocol for a Cross-sectional Observational Study (Preprint)

2020 ◽  
Author(s):  
Lauren Fox ◽  
Jessica Gates ◽  
Ruth De Vos ◽  
Laura Wiffen ◽  
Alexander Hicks ◽  
...  
Keyword(s):  
Health Care ◽  
Hydrogen Peroxide ◽  
Observational Study ◽  
Lung Disease ◽  
Exhaled Breath Condensate ◽  
Exhaled Breath ◽  
Cross Sectional ◽  
Handheld Device ◽  
Respiratory Conditions ◽  
Breath Condensate

BACKGROUND More than 7% of the world’s population is living with a chronic respiratory condition. In the United Kingdom, lung disease affects approximately 1 in 5 people, resulting in over 700,000 hospital admissions each year. People with respiratory conditions have several symptoms and can require multiple health care visits and investigations before a diagnosis is made. The tests available can be difficult to perform, especially if a person is symptomatic, leading to poor quality results. A new, easy-to-perform, point-of-care test that can be performed in any health care setting and that can differentiate between various respiratory conditions would have a significant, beneficial impact on the ability to diagnose respiratory diseases. OBJECTIVE The objective of this study is to use a new handheld device (Inflammacheck) in different respiratory conditions to measure the exhaled breath condensate hydrogen peroxide (EBC H<sub>2</sub>O<sub>2</sub>) and compare these results with those of healthy controls and with each other. This study also aims to determine whether the device can measure other parameters, including breath humidity, breath temperature, breath flow dynamics, and end tidal carbon dioxide. METHODS We will perform a single-visit, cross-sectional observational study of EBC H<sub>2</sub>O<sub>2</sub> levels, as measured by Inflammacheck, in people with respiratory disease and volunteers with no known lung disease. Participants with a confirmed diagnosis of asthma, chronic obstructive pulmonary disease, lung cancer, bronchiectasis, pneumonia, breathing pattern disorder, and interstitial lung disease as well as volunteers with no history of lung disease will be asked to breathe into the Inflammacheck device to record their breath sample. RESULTS The results from this study will be available in 2022, in anticipation of COVID-19–related delays. CONCLUSIONS This study will investigate the EBC H<sub>2</sub>O<sub>2</sub>, as well as other exhaled breath parameters, for use as a future diagnostic tool.

Prognostic Role of Exhaled Breath Condensate pH and Fraction Exhaled Nitric Oxide in Systemic Sclerosis Related Interstitial Lung Disease

2017 ◽  
Vol 53 (3) ◽  
pp. 120-127
Author(s):  
Alfredo Guillen-del Castillo ◽  
Sara Sánchez-Vidaurre ◽  
Carmen P. Simeón-Aznar ◽  
María J. Cruz ◽  
Vicente Fonollosa-Pla ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Systemic Sclerosis ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Exhaled Breath Condensate ◽  
Exhaled Breath ◽  
Prognostic Role ◽  
Breath Condensate ◽  
Fraction Exhaled Nitric Oxide

Cigarette smoke and increased COX-2 and survivin levels in exhaled breath condensate of lung cancer patients: How hot is the link?

Lung Cancer ◽  
2010 ◽  
Vol 67 (1) ◽  
pp. 108-113 ◽  
Author(s):  
Giovanna E. Carpagnano ◽  
Antonio Spanevello ◽  
Grazia P. Palladino ◽  
Claudia Gramiccioni ◽  
Cinzia Ruggieri ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Cigarette Smoke ◽  
Exhaled Breath Condensate ◽  
Exhaled Breath ◽  
Lung Cancer Patients ◽  
Cox 2 ◽  
Breath Condensate

scholarly journals Metabolic Signatures of Lung Cancer in Sputum and Exhaled Breath Condensate Detected by 1H Magnetic Resonance Spectroscopy: A Feasibility Study

2016 ◽  
Vol 9 ◽  
pp. MRI.S40864 ◽  
Author(s):  
Naseer Ahmed ◽  
Tedros Bezabeh ◽  
Omkar B. Ijare ◽  
Renelle Myers ◽  
Reem Alomran ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Magnetic Resonance ◽  
Cancer Patients ◽  
Exhaled Breath Condensate ◽  
Resonance Spectroscopy ◽  
Exhaled Breath ◽  
Lung Cancer Patients ◽  
Metabolic Biomarkers ◽  
Monitoring Treatment ◽  
Breath Condensate

Objectives Lung cancer is one of the most lethal cancers. Currently, there are no biomarkers for early detection, monitoring treatment response, and detecting recurrent lung cancer. We undertook this study to determine if 1H magnetic resonance spectroscopy (MRS) of sputum and exhaled breath condensate (EBC), as a noninvasive tool, can identify metabolic biomarkers of lung cancer. Materials and Methods Sputum and EBC samples were collected from 20 patients, comprising patients with pathologically confirmed non-small cell lung cancer ( n = 10) and patients with benign respiratory conditions ( n = 10). Both sputum and EBC samples were collected from 18 patients; 2 patients provided EBC samples only. 1H MR spectra were obtained on a Bruker Avance 400 MHz nuclear magnetic resonance (NMR) spectrometer. Sputum samples were further confirmed cytologically to distinguish between true sputum and saliva. Results In the EBC samples, median concentrations of propionate, ethanol, acetate, and acetone were higher in lung cancer patients compared to the patients with benign conditions. Median concentration of methanol was lower in lung cancer patients (0.028 mM) than in patients with benign conditions (0.067 mM; P = 0.028). In the combined sputum and saliva and the cytologically confirmed sputum samples, median concentrations of N-acetyl sugars, glycoprotein, propionate, lysine, acetate, and formate were lower in the lung cancer patients than in patients with benign conditions. Glucose was found to be consistently absent in the combined sputum and saliva samples (88%) as well as in the cytologically confirmed sputum samples (86%) of lung cancer patients. Conclusion Absence of glucose in sputum and lower concentrations of methanol in EBC of lung cancer patients discerned by 1H MRS may serve as metabolic biomarkers of lung cancer for early detection, monitoring treatment response, and detecting recurrence.

Sign in / Sign up

Export Citation Format

Share Document